Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Corcoran, Sean R. [1 ,2 ,3 ]
Choi, Jaewoo [4 ]
Fenner, Rachel E. [1 ]
Yu, Xin [4 ]
Scheich, Sebastian [5 ]
Hsiao, Tony [6 ]
Schevchenko, Galina [1 ]
Morris, Vivian M. [4 ]
Phelan, James D. [4 ]
Papachristou, Evangelia K. [7 ]
Kishore, Kamal [7 ]
D'Santos, Clive S. [8 ]
Ji, Yanlong [9 ]
Pittaluga, Stefania [10 ]
Wright, George [11 ]
Urlaub, Henning [12 ]
Pan, Kuan-Ting [13 ]
Oellerich, Thomas [14 ]
Muppidi, Jagan R. [4 ]
Hodson, Daniel James [15 ]
Staudt, Louis M. [4 ]
机构：
[1] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England
[2] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA
[3] NCI, Lymphoid Malignancies Branch, NIH, Boston, MA USA
[4] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD USA
[5] Goethe Univ, Frankfurt, Germany
[6] NCI, NIH, Bethesda, MD USA
[7] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England
[8] Univ Cambridge, Cambridge, England
[9] Max Planck Inst Multidisciplinary Sci, Gottingen, Germany
[10] NCI, Pathol Lab, Ctr Canc Res, Bethesda, MD USA
[11] NCI, Biometr Res Program, Div Canc Treatment & Diag, NIH, Bethesda, MD USA
[12] Max Planck Inst Biophys Chem, Gottingen, Germany
[13] MPI Biophys Chem, Gottingen, Germany
[14] Goethe Univ, Frankfurt, Germany
[15] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178059
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Polatuzumab Vedotin for Diffuse Large B-Cell Lymphoma: Innovation's Allure versus a Time-Honored Tradition
    Singh, Suvir
    Arora, Akriti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2024, 45 (06) : 536 - 537
  • [32] Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
    Topp, Max S.
    Eradat, Herbert
    Florschuetz, Axel
    Hochhaus, Andreas
    Wrobel, Tomasz
    Walewski, Jan
    Knopinska-Posluszny, Wanda
    Kanate, Abraham S.
    Lech-Maranda, Ewa
    Brunnberg, Uta
    Chitra, Surya
    Nielsen, Tina G.
    Sellam, Gila
    Shivhare, Mahesh
    Lossos, Izidore S.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 811 - 817
  • [33] Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
    Eslami, Mohammadreza
    Mehrabi, Mahdi
    Payandeh, Mehrdad
    Saba, Fakhredin
    PLOS ONE, 2024, 19 (08):
  • [34] Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
    Max S. Topp
    Herbert Eradat
    Axel Florschütz
    Andreas Hochhaus
    Tomasz Wrobel
    Jan Walewski
    Wanda Knopinska-Posluszny
    Abraham S. Kanate
    Ewa Lech-Maranda
    Uta Brunnberg
    Surya Chitra
    Tina G. Nielsen
    Gila Sellam
    Mahesh Shivhare
    Izidore S. Lossos
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 811 - 817
  • [35] Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
    Anderson, Kara
    Shehata, Mena
    Singh, Davinder
    Al-Ourani, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [36] Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
    Zhang, Yian
    Yuan, Ling
    Zhuang, Jingli
    Wang, Zhimei
    Zhang, Xuejiao
    Wang, Weiguang
    Liu, Peng
    BLOOD, 2023, 142
  • [37] Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type
    Oka, Satoko
    Ono, Kazuo
    Nohgawa, Masaharu
    ANNALS OF HEMATOLOGY, 2022, 101 (10) : 2353 - 2354
  • [38] Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX
    Liao, Michael Z.
    Deng, Rong
    Gibiansky, Leonid
    Lu, Tong
    Agarwal, Priya
    Dere, Randall
    Lee, Calvin
    Hirata, Jamie
    Herbaux, Charles
    Salles, Gilles
    Li, Chunze
    Miles, Dale
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (12): : 2744 - 2755
  • [39] Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma
    Teruhito Takakuwa
    Yusuke Okayama
    Hirohisa Nakamae
    Masatomo Kuno
    Yosuke Makuuchi
    Naonori Harada
    Hiroshi Okamura
    Mitsutaka Nishimoto
    Yasuhiro Nakashima
    Hideo Koh
    Masayuki Hino
    Annals of Hematology, 2022, 101 : 1609 - 1610
  • [40] Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma
    Bourbon, Estelle
    Salles, Gilles
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (10) : 1079 - 1088
12345